Oregon Department of Justice

Attorney General Ellen F. Rosenblum

Oregon Department of Justice - Attorney General Ellen F. Rosenblum
submit button to get updates about the Department of Justice
subscribe to RSS feed   visit Oregon.gov

OREGON DEPARTMENT OF JUSTICE ANNOUNCES $100 MILLION CONSUMER PROTECTION PHARMACEUTICAL AGREEMENT

May 7, 2012

Oregon will receive $3.9 million under the national consumer protection settlement agreement with Chicago-based Abbott Laboratories

Oregon Attorney General John Kroger today announced a $100 million multistate agreement with global health care and medical research company Abbott Laboratories over off-label promotional claims related to its drug Depakote®. This agreement marks the largest ever consumer protection-based pharmaceutical settlement.

"Protecting consumers from drug companies that use unscrupulous sales tactics is a top priority of the Department of Justice," said Attorney General Kroger.

Oregon organized and co-led the multistate investigation into Abbott's promotion of Depakote®, a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat seizure disorders, mania associated with bipolar disorder and migraines. The investigation yielded evidence that Abbott representatives engaged in unfair and deceptive practices when it marketed the drug for uses not approved by the FDA; specifically, schizophrenia, and agitation associated with dementia.

The Complaint alleges that although Abbott could not substantiate its claim that Depakote is effective for the treatment of agitation associated with dementia, or as adjunct therapy with antipsychotics to treat schizophrenia, the company bypassed the regulatory process and actively promoted the drug off-label to treat these indications.

To bolster Depakote schizophrenia sales, Abbott promoted a clinical trial that was not sufficient for FDA approval but showed Depakote to be marginally effective for this indication. Subsequently, Abbott conducted a second clinical trial that showed Depakote was ineffective for the treatment of schizophrenia. Nevertheless, Abbott sales representatives allegedly continued to distribute and detail the positive study without disclosing the details of the negative study.

Abbott also allegedly distributed and promoted studies that were weak evidence that Depakote was effective for treatment of agitation associated with dementia despite the fact that Abbot knew of a stronger study that found Depakote to be ineffective for this indication.

Under the stipulated judgment filed today in Multnomah County Circuit Court, Abbott Laboratories will pay $100 million to the settling states and make significant reforms to its marketing practices and cease. As one of two lead states, Oregon will recover a total of $3, 569,179 under the settlement.  The Department of Justice was also able to negotiate an additional payment of $283,000 to reimburse the Public Employees Benefit Board (PEBB), State Accident Insurance Corporation Fund (SAIF), Oregon State Hospital, Oregon Youth Authority and the state Department of Corrections to recover that portion of Depakote purchases by these agencies that were associated with off-label uses.

"We are pleased to participate in efforts to recover these costs. We know inmate health care is expensive and every dollar we can recover matters. This settlement is about fiscal responsibility and accountability to taxpayers," said Department of Corrections Director Colette S. Peters.

In conjunction with the monetary terms of the agreement, the multistate settlement prohibits Abbott from making false or misleading claims about Depakote and promoting the drug for off-label uses. The company is required to ensure that any financial incentives on sales do not promote off-label uses of Depakote.

For a five-year period, Abbott must also:

  • Limit the creation and use of responses to requests by physicians for
    non-promotional information about off-label uses of Depakote;
  • Limit dissemination of reprints of clinical studies relating to off-label uses of Depakote;
  • Limit use of grants and continuing medical education and disclose payments to physicians; and
  • Register and disclose clinical trials.

Assistant Attorney-in-Charge of the Financial Fraud/Consumer Protection Section David Hart and Senior Assistant Attorney General Lucille Salmony handled this case for the Oregon Department of Justice.

Attorneys General of the District of Columbia and the following states participated in today's settlement:  Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia and Wisconsin.

Attorney General John Kroger leads the Oregon Department of Justice. The Department's mission is to fight crime and fraud, protect the environment, improve child welfare, promote a positive business climate, and defend the rights of all Oregonians.

 

Contact:

Tony Green, (503) 378-6002 tony.green@doj.state.or.us |
email this page print this page check the site map